Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-RESIST
2020-004832-48Phase 3Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in heart failure (HF) comparing Dapagliflozin arm with Metolazone arm (2 arms). Primary endpoint: Diuretic effect by weight change. Status: unknown.
02
Drugs
dapagliflozinmetolazone
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2020-004832-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004832-48.